-
GW4064: A Practical Non-Steroidal FXR Agonist
2026-08-17
GW4064 provides a potent, selective way to activate FXR while connecting receptor assays with bile acid efflux, lipid regulation, and hepatotoxicity workflows. This guide covers compound handling, assay design, reference-informed rescue experiments, and troubleshooting for reproducible metabolic research.
-
Protease Inhibitor Cocktail: EDTA-Free Use
2026-08-16
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolysis during protein extraction and downstream assays while avoiding EDTA-mediated chelation. It is appropriate for EDTA-sensitive workflows such as phosphorylation analysis, but it should not be treated as a substitute for metalloprotease inhibition when EDTA is required.
-
CaCl2 Effects on Amyloid-β Aggregation at Membranes
2026-08-15
This 2024 study applies supercritical angle Raman and fluorescence methods to distinguish amyloid-beta behavior at lipid surfaces from signals in bulk solution. Its central finding is that a calcium-ion layer can protect membranes from peptide insertion, while calcium has a stronger effect on Aβ1–42 than on the 40-residue isoform.
-
Digoxin Workflows for Cardiac and Antiviral Research
2026-08-14
Digoxin provides a mechanistically defined way to study Na+/K+ ATPase inhibition, cardiac contractility modulation, and cell-type-specific chikungunya virus responses. This practical guide connects dose design, exposure-aware assays, controls, and troubleshooting for more reproducible cardiovascular and antiviral experiments.
-
Proteinase K Workflows for DNA Purity
2026-08-14
Proteinase K combines broad protein digestion with compatibility across detergents, chelators, and DNA-isolation conditions. This guide translates its biochemical strengths into practical genomic DNA workflows while using a SARS-CoV-2 protease-screening study to sharpen assay controls and troubleshooting decisions.
-
LARP1, TOP mRNAs, and Repressed Ribosome Complexes
2026-08-13
Saba and colleagues define how LARP1 directly associates with non-translating ribosomal subunits and how this interaction relates to TOP mRNA repression. Cryo-EM and biochemical experiments reveal a ribosome-contacting LARP1 domain while showing that ribosome binding is not required for TOP repression or stabilization, revising prevailing models of repressed TOP complexes.
-
Belinostat: Interpreting HDAC Drug Responses
2026-08-13
Belinostat (PXD101) is a potent pan-HDAC inhibitor for studying chromatin remodeling and cancer-cell responses. This article presents a response-phenotyping framework that separates proliferation arrest from cell death, improving interpretation of bladder and prostate cancer assays.
-
(R,S)-Anatabine: A Translational Strategy for Aβ
2026-08-12
Alzheimer’s disease research increasingly depends on mechanistic resolution rather than single-endpoint peptide measurements. This thought-leadership guide examines how (R,S)-Anatabine connects APP β-cleavage, BACE-1 expression, Aβ reduction, and NF-κB signaling across cell-based and transgenic mouse models, while outlining practical assay, material-handling, and translational strategies.
-
BMN 673: A Splicing-Informed PARP Strategy
2026-08-12
BMN 673 (Talazoparib) enables a deeper PARP research strategy that connects DNA damage responses with spliceosome-dependent biomarkers. This article translates recent hepatocellular carcinoma findings into practical assay and study-design decisions.
-
U0126: Practical MEK1/2 Inhibition Workflows
2026-08-11
U0126 is a cell-permeable, non-ATP-competitive MEK1/2 inhibitor for resolving ERK-dependent signaling in cancer, neurobiology, and degradative-pathway assays. This guide connects pathway pharmacology with a recent orofacial pain study, offering practical controls, protocol starting points, and troubleshooting strategies.
-
(R,S)-Anatabine: Evidence-Aware Assay Design
2026-08-11
Explore how (R,S)-Anatabine supports amyloid-beta and neuroinflammation studies, and learn what NLRP10 skin-barrier research teaches about selecting mechanistically informative assays.
-
BRD4770: Translating G9a Biology Into Cancer Strategy
2026-08-10
BRD4770 connects G9a-driven H3K9 methylation with senescence and tumor-cell proliferation, offering translational researchers a focused chemical probe for testing epigenetic dependencies across cancer models.
-
Clasto-Lactacystin β-lactone in RIPK3 Research
2026-08-09
Clasto-Lactacystin β-lactone provides a powerful way to test whether RIPK3 loss is proteasome-dependent during virus-induced necroptosis. This article translates a landmark host–virus study into a rigorous assay strategy while clarifying what pharmacological proteasome blockade can—and cannot—prove.
-
MK-5108 (VX-689) in Aurora A Research
2026-08-08
MK-5108 (VX-689) combines subnanomolar Aurora A potency with substantially weaker Aurora B and C activity, making it useful for mechanistic cell-cycle studies and cancer cell line proliferation assays. This workflow-focused guide shows how to prepare, deploy, interpret, and troubleshoot the compound while translating new retinoblastoma evidence into testable research strategies.
-
Annexin V-PE Reagent for CAR-T Cell Death Assays
2026-08-07
The Annexin V-PE Reagent provides a rapid phosphatidylserine externalization readout for distinguishing early apoptotic events from later loss of membrane integrity. In CD38 CAR-T studies, it can complement cytotoxicity measurements by tracking target-cell killing, T-cell fratricide, and construct-dependent safety signals in the same experimental workflow.